NCT03098550 | Study Connect

Ask a Question

Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others

* Required field

Your Email Address *

Please enter a valid email address.

Choose a Topic *

Tell us your question and any additional information *

Please enter all required fields.

Please Log In/Join Now first, and then use this function!

Active, Not Recruiting

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread - CA209-9GW

Updated: 24 June, 2020 | ClinicalTrials.gov

About This Trial
Key Eligibility Criteria

Print Friendly Summary

CONSIDERING THIS TRIAL?

Print this page and the trial guide to help you talk with your doctor.

Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Print this page CA209-9GW

Download Study Participant’s Guide

SELECT LANGUAGE

Trial Details

Phase 1/Phase 2

Phase
Gender(s)
18+

Age Range
Active, Not Recruiting

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Experimental: Immunotherapy Combination

Biological: Nivolumab Biological: Daratumumab

Experimental: Nivolumab Monotherapy

Biological: Nivolumab

Key Eligibility Criteria

Inclusion Criteria: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com - Patients with metastatic or advanced solid tumors - Women with histologically or cytologically confirmed triple negative breast carcinoma - Participants with histologically or cytologically confirmed pancreatic adenocarcinoma - Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC) Exclusion Criteria: - Active brain metastases or leptomeningeal metastases. - Any serious or uncontrolled medical disorder - Prior malignancy active within the previous 3 years Other protocol defined inclusion/exclusion criteria could apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -

Call 855-907-3286 or email clinical.trials@bms.com